All Allergan articles
-
News briefs
Bausch + Lomb appoints former CEO as new CEO
Bausch + Lomb has announced the appointment of Brent Saunders to the position of CEO, succeeding Joseph Papa, effective March 3. Saunders, who will also serve as chair of the board of directors, is already familiar with Bausch + Lomb as he was its CEO between 2010 and 2013, prior ...
-
News briefs
Allergan gets FDA approval for presbyopia eye drop
Allergan has announced the approval that its VUITY eye-drop presbyopia solution had just received the approval of the U.S. Foods & Drugs Administration (FDA). Phase 3 clinical studies have showed that VUITY, based on a formulation of pilocarpine and delivered by the company’s proprietary technology pHast, improved near and intermediate ...
-
News briefs
AbbVie completes acquisition of Allergan
AbbVie , the U.S. biopharmaceutical group, has completed the acquisition of Allergan , an Irish-domiciled pharmaceutical company, following receipt of regulatory approval from all government authorities required by the transaction agreement. Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each share held. Allergan common stock ...
-
News briefs
Allergan's Q4 revenues up
Allergan ’s fourth-quarter revenues rose by 6.6 percent to $4,351million. The group posted an operating loss of $276.6 million for the period compared with an operating loss of $5,384 million a year earlier. On an adjusted basis, it booked an operating income of $2.079 million, up by 8.4 percent. Allergan ...
-
News briefs
Abbvie and Allergan enter agreement with FTC
Abbvie and Allergan have entered into a consent decree agreement with the staff of the U.S. Federal Trade Commission (FTC) regarding AbbVie’s acquisition of Allergan. Under the terms of the consent decree, the companies have agreed to divest brazikumab , an investigational inhibitor in the development for autoimmune diseases, to ...
